An import of medicinal cannabis from Portugal to Germany signifies the largest quantity ever moved within the EU, highlighting a surge in the medicinal cannabis products market.
List view / Grid view
Drug Supply Chain
Filter the results
The Operation Yellowhammer document has been published, which states that the UK will experience severe delays to the medical supply chain following a no-deal Brexit.
Two Tennessee companies have been prevented from distributing drugs after a complaint they were supplying unapproved medications.
A ban on Indian trade to Pakistan has been partly changed to allow the import of drugs after a shortage of critical medicine.
The voretigene neparvovec gene therapy treatment has been highlighted in draft guidance by NICE for availability on the NHS.
The Chinese pharmaceutical industry has been lagging behind in terms of drug development and bringing new products to the market. In this article, Megha Baruah discusses the changes the National Medical Products Administration (NMPA) of China is making to existing policies and informs on guidance documents that have been released…
In February this year the EU Falsified Medicines Directive (FMD) came into effect. Rich Quelch assesses this latest regulatory attempt to rid the supply chain of dangerous falsified products and reflects on the industry’s need to keep ahead of the game to future-protect itself.
The articles in this In-Depth Focus delve into the effectiveness of the FMD and why it is necessary as well as how drug manufacturers need to become innovative in their processes.
A statement from 11 health union leaders highlights the possibility of severe drug shortages if the UK leaves the EU without a deal.
Around half of HRT products have been reported as out of stock in UK pharmacies due to supply issues in China, leading to a shortage.
A leaked government dossier has stated that in the event of a no-deal Brexit, the UK will face severe medicinal shortages.
The CMA alleges that Aspen broke competition law, prompting the drug supplier to offer a payment and other compensations to the NHS.
An open letter has underscored the challenges of return failure in the US drug supply chain, especially after the introduction of the Drug Supply Chain Security Act in November.
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.